Longeveron to Participate in Three Longevity/Aging Investment Conferences

New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce Neuroinflammation in the Brain, A Core Driver of AD Pathogenesis, Published on medRxivMIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. NASDAQ:LGVN, a clinical stage…